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Abstract
The present study evaluates the cranio‑facial growth 
disorders in a series of patients suffering from pituitary 
dwarfism, as a result of the therapy with recombinant 
human growth hormone (rhGH). Included in the study 
were 15 children diagnosed with pituitary dwarfism in the 
Endocrinology Clinics of the ”Sf. Spiridon” Hospital of 
Iasi, subjected to a treatment with rhGH for 2 years. After 
the application of the therapy, the parameters of general 
physical development were followed and the dental ortho‑
pantomography and profile cephalometry were analyzed. 
The results obtained confirm a general physical growth of 
about 1.3 cm/month in the first year of treatment, followed 
by values around 1.1 cm/month in the second year. 
Cranio‑facial development was improved by the increase 
of both mandibular vertical branch and facial height. At 
the level of the dental arches, one could observe improved 
sagital and transversal relations at molar level, as well as 
a regulating tendency of dental eruption. The therapy with 
rhGH is thus influent at cranio‑facial level, favourizing the 
development of maxillaries, regulation of dental eruption 
and the aesthetic aspects. 
Keywords:  craniofacial skeleton,  growth  hormone  defi‑
ciency, growth hormone replacement therapy.
INTRODUCTION
The different complexity of the cranio‑facial 
manifestations in pituitary dwarfism requires 
therapeutical solutions capable of correcting not 
only the disfunctional potential (even if non‑ 
validating), but also the aesthetic prejudices, 
whose importance is increasingly justified.
The diagnosis of the cranio‑facial modifica‑
tions should synthesize an ample action, based 
on a minute clinical investigation within which 
these modifications – analyzed in detail – should 
permit the elaboration of an investigation pro‑
gram  favourizing  certification,  detailing  and 
control of the evolution within a correction 
therapeutical program. 
MORPHO‑FUNCTIONAL RE‑ESTABLISHMENT OF CRANIO‑FACIAL 
GROWTH DISORDERS IN PITUITARY DWARFISM BY RHGH THERAPY
Adriana BĂLAN1, Marinela PĂSĂREANU2, Vasilica TOMA3, Irina Nicoleta ZETU4
1.  Associate Prof., PhD, Pedodontics, Faculty of Dental Medicine “Gr.T. Popa” UMPh of Iasi
2.  Associate Prof., PhD, Pedodontics, Faculty of Dental Medicine “Gr.T. Popa” UMPh of Iasi
3.  Lecturer, PhD, Pedodontics, Faculty of Dental Medicine “Gr.T. Popa” UMPh of Iasi
4.  Associate Prof., PhD, Ortodontics and Dental‑Facial Orthopedy Faculty of Dental Medicine, “Gr.T. Popa” UMPh of Iasi
Contact person: tomamariuscristian@yahoo.com
The differences noticed in the relative increase 
of the various cranio‑facial components have 
been acknowledged for quite a long time. One of 
the first investigators to quantify relative facial 
growth was Hellman, who described the length 
and depth of the face as uniform along time; at 
regional level, he measured relative length, rela‑
tive width and inferior depth. Hellman’s 
cross‑sectional comparisons indicated that, even 
starting with very young ages, facial width may 
attain maturity more rapidly than facial depth 
which, in its turn, tends to be more mature than 
facial depth [1].
In 1979, Baugan et al. introduced three types 
of distinct growth processes, including a cranial 
pattern for cranium and cranium basis, a facial 
pattern for the maxillary and the mandible, and 
a general pattern for the long bones of the body. 
The cranial basis was characterized as having the 
lowest relative increase and the least intense 
pubertary increase, the facial pattern being 
enlarged with about 1.5‑2% per year, while stat‑
ure grew with 3.5% each year. Four years later, 
Buschang et al. demonstrated that growth of the 
cranio‑facial complex actually represents a math‑
ematical integral over the neural and general 
curves of Scammon [2]. Buschang et al. intro‑
duced the notion of gradient of maturity of 
cranio  facial growth (CFGMG), covering the area 
from head’s height up to the anterior cranial 
basis. Even if the cranio‑facial compounds of 
girls are considered more mature than those of 
boys, the gradient of variation among sizes does 
not depend on sex [1,2]. 
As a result of the general epigenetic effects, 
GH assures an excellent test for such a 
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hypo  thesis. GH has been recognized as a major 
factor in controlling somatic growth and matur‑
ization, its effects depending on the duration of 
the treatment. However, the impact of GH defi‑
ciency or that of its therapeutic suplimentation 
upon the cranio‑facial complex has not been 
thoroughly analyzed with regard to the CFGMG 
pattern [1,3].
MATERIALS AND METHOD
The study was performed on a group of 15 
children (8 boys and 7 girls) from the region of 
Moldova, diagnosed with pituitary dwarfism in 
the Endocrinology Clinics of the “Sf. Spiridon” 
University  Hospital  of  Iaşi,  and  treated  with 
rhGH for 2 years.
 Selection of the pituitary dwarfism cases was 
based on the inclusion criteria recommended by 
the National Program of treatment with growth 
hormone, as follows:
•  severe cases, showing a deficit exceeding 
3DS and which, usually, respond to not 
very high rhGH doses;
•  presumed receptivity of the patient to the 
treatment;
•  evaluation of a bone age of maximum 11 
years;
•  evidencing of the somatic growth deficit 
by means of specific provocative tests (the 
test to arginine, the test to induced 
hypoglycemia, the test of stimulation with 
clonidine), subordinated to the principle 
according to which two concordant tests 
bear the significance of an inclusion crite‑
rion (or of a significant test and of an IGF1 
value below the average ones – i.e. lower 
than ½ of them).
The exclusion criteria considered included:
•  confirmation  of  a  benign  or  malignant 
tumour (including the thyroidian nodule, 
leukemias and craniopharyngioma);
•  bone age older than 11 years, correlated 
with the occurrence of the secondary 
sexual features;
•  absence of response to the treatment (a 
growth ratio below 5 cm per year);
•  the impossibility of  assuring a protheic 
ratio;
•  QI > 70.
The norms of therapeutical posology refer to 
an equivalent initial dose of 0.1 UI/kgc/week, 
with the appreciation of a satisfaction response 
at a growth ratio of 1 cm/month. For a growth 
ratio below 0.5 cm/month,  double doses have 
been administered, attainment of a dose > 0.2 
Ul/kgc/week requiring the identification of the 
interference factors.
The Genotropin (KabiPharm, 16 UI/f) and 
Norditropin (Novo‑Nordisk) preparations have 
been employed. The administration schemes 
were different, with the exception of the 6 days/
week one.
Selection, out of the total number of treated 
cases, of only 15 children, is caused by the scarce 
available documentation, restricted to the thera‑
peutical start of the cranio‑facial evaluations. 
Also selected were some cases which involved 
comparable therapeutical intervals (2 years). The 
children were examined clinically, generally and 
stomatologically, according to the study pat‑
terns, dental orthopantomography and profile 
cephalometry (figure 1).
Fig. 1: Landmarks and reference lines used for 
linear and angular measurements on 
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RESULTS
The general physical development following 
the treatment with rhGH registered a stature 
growth of approximately 1.3 cm/month in the 
first year and of 1.1 cm/month, respectively, in 
the second year of treatment. Analysis of the pro‑
file teleradiographies after 2 years of treatment 
evidenced improvement of the linear and angu‑
lar values, comparatively with the standard val‑
ues, as a function of age, manifested especially 
by the growth of the horizontal and vertical 
branches of the mandible, by a minimum growth 
of the dimensions of the clivus – which cause 
anterior facial rotation. 
The measurements taken at the level of the 
patterns of study showed an obvious melioration 
of the sagital relations at molar level, while the 
deficit – both the sagital and the tranversal one 
– is not wholly recovered at the level of the 
dento‑alveolar arches (with an average recovery 
of approx. 2‑3 mm). The orthopantomographies 
show an accelerated rhythm of dental eruption, 
so that, after the treatment, the dental age is cor‑
related with the chronological one (figure 2).
Prior to the treatment with rhGH
2 years after the treatment with rhGH
Fig. 2: The RC case – Orhtopantomographies taken 
prior to and after the treatment with rhGH
DISCUSSION
Cranio‑maxillo‑facial development in pitui‑
tary dwarfism is harmoniously correlated with 
the hypostature development, the patients gen‑
erally showing a smaller cephalic brain pan, with 
a tendency towards brachicephalia. The facies is 
ovoidal, with the features of a mesoprosope one, 
with tendency towards euryprosopic face. Men‑
tion should be made of an uneven development 
of the facial zones, both vertically and transver‑
sally, while the weakly developed facial massive 
acquires the ”doll aspect”, most frequently put 
into evidence by an “in future” pigmentation of 
the cheek bones, with an area of oro‑nasal pale‑
ness. The face is delicate, gracile, these patients 
preserving a specific childish aspect untill reach‑
ing adolescence. Later on, the teguments of the 
face get soon wrinkled, the facies having an 
aspect of precocious oldness (of the infanto‑senes‑
cent type). The eyes are expressive, with hypo‑
telorism, oblique, small and round. The nasal 
pyramid is weakly developed, with small and 
round nostrils. The mentoniere region is small, 
dull, with mandibular retrognatism. The profile 
is convex, with the labial part normal or stressed. 
The hypoplasic larynx will determine a high‑ 
pitched voice [4].
By the insufficient bone development, in gen‑
eral, and facial massive bones, especially, the 
oral cavity is small, with hypoplasic dental arches 
and micrognathism, elements induced by the 
insufficiency of the pituitary growth hormone. 
This bone structure of the maxillaries will cause 
dento‑alveolar disharmonies, dental malposi‑
tions, included teeth. As to the volume, the teeth 
may be either reduced or normal in size. Apart 
from the volume anomalies, mention should be 
also made, in pituitary dwarfism, of anomalies 
in number, position and structure. Also possible 
is the dental eruption delayed, on the average, 
with 3 and even 5 years, and preservation, on the 
arch, of the temporary teeth up to the adolescent 
years. Affectation of the marginal periodontium 
is precocious and sometimes severe and, besides 
the local irritation caused by the oral hygiene, 
the periodontal inflammation may be also deter‑
mined by the higher presence of alkaline phos‑
phatases in the gingival mucous membrane [5].International Journal of Medical Dentistry 169
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Reports upon the dentition and facial struc‑
ture in children with deficit of GH (hypopituita‑
rism) have been initiated in the 30’ies and 40’ies. 
Based on singular cases, they described the 
delayed dental and facial development. In time, 
extended analyses demonstrated delays in the 
dental, facial and cranial base development [5,6].
It was observed that delayed dental develop‑
ment is always less pronounced than that of stat‑
ure or of the bone age. In a group of 25 patients 
with GH deficit, Sinikka Pirinen [7] asserted that 
the deficit of dental development is progressive, 
varying among 1‑6 standard deviations (SD). 
Dentition appears as harmoniously delayed, so 
that all components taken into study for dental 
development (resorption of decidual teeth, for‑
mation of permanent teeth and change of denti‑
tion) evoke the same delay degrees.
The GH begins to influence the linear growth 
almost from the 9th month. However, few papers 
have been devoted to the eruption of decidual 
teeth in children with deficit of GH. Anamnesti‑
cally, an either normal or slight time delay is 
appreciated.
The observations made on Lewis rats with 
deficit of GH evidence a small population of 
odontogenous cells with a reduced number of 
mitoses.
The children with deficit of GH present a dis‑
parity in their neuro‑ and viscero‑cranial devel‑
opment (neurocranium with a significant 
development comparatively with the viscerocra‑
nium) at an IQ over the one corresponding to 
age. Cephalometric studies showed low dimen‑
sions of the anterior and posterior zones of the 
cranium base.
Analyzing 21 cases of either isolated or com‑
bined hypophisary deficit, Sinikka Pirinen [7] 
demonstrated the low sizes of the cranial base 
and the reduced mandibular posterior height in 
patients  with  GH  deficit,  comparatively  with 
healthy subjects of the same stature from a con‑
trol group. Within the same group, in a signifi‑
cant number of cases, a comparatively higher 
height of the face (N‑ANS) was also evidenced.
In a study proposed as a master thesis at the 
University of Michigan, elaborated in 1992, 
Krista A. Richey communicates the results of the 
therapeutical effects of GH upon the dento‑alve‑
olar development in children with idiopatic 
hypostature, starting from the suggestion of the 
Genentech Joint Group Study, according to 
which 50% of the ill ones would respond to the 
human recombinant growth hormone. From this 
perspective, the author evaluated teeth sizes, the 
modifications in the sizes of the dental arches 
and of the dento‑alveolar disharmonies along a 
5 year‑treatment with human recombinant   
growth hormone on 31 children with idiopatic 
hypostature,  on applying hypopituitarism as a 
pattern for the approach and analysis of the den‑
tal parameters. Negligible differences are 
recorded between the sizes of arch evaluated 
pre‑therapeutically and immediately after initia‑
tion of the treatment and, again, insignificant dif‑
ferences among the latter ones and those 
re‑evaluated one year after the initiation of the 
treatment with recombinant growth hormone. In 
spite of the statistically‑significant trend, esti‑
mated for the relative sizes of the arch during   
prolongued treatment, the therapeutical effects 
of the long‑term administration are viewed as 
speculative [8,9].
The dento‑alveolar disharmonies of the sub‑
jects with hypostature, measured by the occlusal 
index, are slightly increased during the investi‑
gation interval, while the influence of the  human 
recombinat growth hormone upon the modifica‑
tions of the dento‑alveolar unbalance remain 
uncertain.
CONCLUSIONS
The results of the rhGH therapy in pituitary 
dwarfism  confirmed  the  improvement  of  the 
facial traits, materialized in anterior facial rota‑
tion and accelerated rhythm of dental eruption, 
thus counterbalancing the cranio‑facial growth 
disorders, all of them contributing to achieving 
a really important aesthetic effect.
The restricted number of cases and the control 
interval during the treatment with growth hor‑
mones, added to the different ages of the subjects 
included in the study in the beginning of the 
treatment, with which the receptivity to growth 
hormones is undoubtedly correlated, do not per‑
mit drawing of quantifiable conclusions. In the 
subjects here under investigation, our observa‑
tions have mainly outlined the main tendencies 
to be developed and confirmed in future 
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